ALK-Abelló A/S
ALK-B
Kedudukan dalam Saham
#2327
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Harga Saham
$36.45
Modal Pasaran
$8.09B
Perubahan (1 hari)
-3.46%
Perubahan (1 tahun)
10.38%
Negara
DK
Perdagangan ALK-Abelló A/S (ALK-B)
Kategori
Healthcare
Hasil untuk ALK-Abelló A/S (ALK-B)
Hasil pada Jun 2026 TTM: $1.08B
Menurut laporan kewangan terkini daripada ALK-Abelló A/S, hasil semasa syarikat (TTM) ialah $1.08B. Pada tahun 2023, syarikat memperoleh hasil sebanyak $714.26M peningkatan berbanding hasil pada tahun 2022 iaitu $649.28M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi ALK-Abelló A/S dari 2004 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $1.08B | 40.35% |
| 2024 | $772.54M | 8.16% |
| 2023 | $714.26M | 10.01% |
| 2022 | $649.28M | 8.42% |
| 2021 | $598.86M | 4.50% |
| 2020 | $573.06M | 16.63% |
| 2019 | $491.36M | 9.76% |
| 2018 | $447.68M | -4.54% |
| 2017 | $468.95M | 9.96% |
| 2016 | $426.48M | 13.93% |
| 2015 | $374.34M | -5.40% |
| 2014 | $395.69M | -4.38% |
| 2013 | $413.80M | -0.22% |
| 2012 | $414.70M | 1.41% |
| 2011 | $408.93M | 5.61% |
| 2010 | $387.20M | 3.63% |
| 2009 | $373.63M | 12.03% |
| 2008 | $333.50M | 2.67% |
| 2007 | $324.83M | 23.62% |
| 2006 | $262.76M | 36.41% |
| 2005 | $192.63M | -76.45% |
| 2004 | $817.87M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 1,064.32% |
US
|
|
| $2.23B | 105.49% |
US
|
|
| $15.74B | 1,352.08% |
AU
|
|
| $6.02B | 455.34% |
NL
|
|
| - | - |
CH
|
